Combined modality treatment for early-stage Hodgkin’s lymphoma: the GHSG experience
S. Sasse, V. Diehl, A. Engert
University Hospital of Cologne, Germany Dept. I of Internal Medicine, Köln, Germany
The prognosis of patients has substantially improved over the last decades. Currently, approximately 80% of all patients remain disease free 5 years after treatment.1 On the basis of clinical staging and risk factors as listed in Table 1 patients with Hodgkin lymphoma (HL) are usually classified into early favourable stages (CS 1-2 without risk factors), early-unfavorable stages (CS I-II with risk factors) or advanced stages. Here, we report on the experience of the GHSG and others in the treatment of early favourable and unfavourable HL.